consensus statement on the use of intravenous recombinant tissue plasminogen activator to treat acute ischemic stroke by the chinese stroke therapy expert panel

CNS Neuroscience and Therapeutics

Volumn 19, Issue 8, 2013, Pages 543-548

  Xu, An Ding ^a   Wang, Yong Jun ^b   Wang, David Z ^c  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c OSF Healthcare System   (United States)

Author keywords

Acute ischemic stroke; Consensus; Fibrinolysin; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; GLUCOSE; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD PRESSURE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FIBRINOLYTIC THERAPY; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HEART ATRIUM FIBRILLATION; HUMAN; NEUROIMAGING; PRACTICE GUIDELINE; PUBLICATION; RECOMMENDED DRUG DOSE; RISK ASSESSMENT;

ACUTE ISCHEMIC STROKE; CONSENSUS; FIBRINOLYSIN; TISSUE PLASMINOGEN ACTIVATOR;

ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN ISCHEMIA; HUMANS; INJECTIONS, INTRAVENOUS; RECOMBINANT PROTEINS; RISK FACTORS; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84880698449     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12126     Document Type: Article

References (40)

1. Chinese consensus expert panel for intravenous recombinant tissue plasminogen activator for acute ischemic stroke. Consensus statement on intravenous recombinant tissue plasminogen activator to treat acute ischemic stroke. Chin J Intern Med 2006; 45: 613-614.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engle J Med 1995;333:1581-1587.
3. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.
4. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-282.
5. Liao XL, Wang YL, Wang CJ, et al. Thrombolysis with intravenous recombinant tissue plasminogen Activator 3 to 4.5 h after acute ischemic stroke in China. Stroke 2012;43:A62.
6. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012;379:2364-2372.
7. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
8. Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-874.
9. Lees KR, Bluhmki E, von Kummer R, et al., ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-1703.
10. Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379:2352-2363.
11. Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006;37:1810-1815.
12. Nakagawara J, Minematsu K, Okada Y, et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010;41:1984-1989.
13. Dharmasaroja PA, Pattaraarchachai J. Low vs standard dose of recombinant tissue plasminogen activator in treating East Asian patients with acute ischemic stroke. Neurol India 2011;59:180-184.
14. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-2118.
15. Larrue V, Von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke, potential contributing factors in the European cooperative acute stroke study. Stroke 1997;28:957-960.
16. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) Cohort. Stroke 1999;30:2280-2284.
17. Larrue V, von Kummer RR, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-441.
18. Molina CA, Montaner J, Abilleira S, et al. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke 2001;32:1079-1084.
19. Lou M, Safdar A, Mehdiratta M, et al. The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology 2008;71:1417-1423.
20. Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012;43:1524-1531.
21. Lyden PD. Stroke: haemorrhage risk after thrombolysis-the SEDAN score. Nat Rev Neurol 2012;8:246-247.
22. Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR, VISTA Collaborators. Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010;41:2840-2848.
23. Bhatnagar P, Sinha D, Parker RA, Guyler P, O'Brien A. Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age. J Neurol Neurosurg Psychiatry 2011;82:712-717.
24. Frankel MR, Morgenstern LB, Kwiatkowski T, et al. Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology 2000;55:952-959.
25. Molina CA, Montaner J, Abilleira S, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2001;32:2821-2827.
26. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC. Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology 2003;61:71-75.
27. Vergouwen MD, Casaubon LK, Swartz RH, et al. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke 2011;42:1041-1045.
28. Xian Y, Liang L, Smith EE, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 2012;307:2600-2608.
29. Smith EE, Fonarow GC, Reeves MJ, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke 2011;42:3110-3115.
30. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 2005;46:243-252.
31. Khatri P, Kleindorfer DO, Yeatts SD, et al. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke 2010;41:2581-2586.
32. De Keyser J, Gdovinová Z, Uyttenboogaart M, Vroomen PC, Luijckx GJ. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke 2007;38:2612-2618.
33. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
34. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-1231.
35. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8:141-150.
36. Ma H, Parsons MW, Christensen S, et al. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012;7:74-80.
37. Schonewille WJ, Wijman CA, Michel P, et al. Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol 2009;8:724-730.
38. Lindsberg PJ, Mattle HP. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke 2006;37:922-928.
39. Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 2011;123:750-758.
40. Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke 2011;42:1658-1664.